MYRIAD GENETICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.39 USD | +0.18% |
|
-3.90% | +17.08% |
| May. 31 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
| May. 31 | Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT |
Financials (USD)
| Sales 2024 * | 831M | Sales 2025 * | 897M | Capitalization | 2.02B |
|---|---|---|---|---|---|
| Net income 2024 * | -92M | Net income 2025 * | -64M | EV / Sales 2024 * | 2.32 x |
| Net cash position 2024 * | 93.93M | Net cash position 2025 * | 116M | EV / Sales 2025 * | 2.13 x |
| P/E ratio 2024 * |
-23.8
x | P/E ratio 2025 * |
-31.9
x | Employees | 2,700 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Myriad Genetics, Inc.
More recommendations
More press releases
More news
| 1 day | -1.80% | ||
| 1 week | -3.50% | ||
| Current month | -1.80% | ||
| 1 month | +14.79% | ||
| 3 months | +0.77% | ||
| 6 months | +16.22% | ||
| Current year | +16.77% |
1 week
21.76
23.20
1 month
19.4725.95
Current year
17.1825.95
1 year
13.8225.95
3 years
13.8236.95
5 years
9.2448.40
10 years
9.2450.44
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Diaz
CEO | Chief Executive Officer | 61 | 20-08-12 |
Scott Leffler
DFI | Director of Finance/CFO | 49 | Jan. 28 |
Dale Muzzey
CTO | Chief Tech/Sci/R&D Officer | 44 | 14-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
S. Phanstiel
CHM | Chairman | 65 | 09-09-15 |
Paul Bisaro
BRD | Director/Board Member | 63 | 22-10-30 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 20-05-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.24% | 14 M€ | -5.04% | ||
| 0.26% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 22.39 | +0.18% | 438 396 |
| 24-06-03 | 22.35 | -1.80% | 944,210 |
| 24-05-31 | 22.76 | +1.34% | 597,434 |
| 24-05-30 | 22.46 | -1.06% | 576,077 |
| 24-05-29 | 22.7 | -2.66% | 494,892 |
Delayed Quote Nasdaq, June 03, 2024 at 04:00 pm EDT
More quotes
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.
Calendar
2024-06-06
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
22.35
USD
Average target price
25.09
USD
Spread / Average Target
+12.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.77% | 2.02B | |
| -4.27% | 12.39B | |
| -0.60% | 8.43B | |
| +7.21% | 5.77B | |
| +33.95% | 5.76B | |
| -10.21% | 4.1B | |
| +10.62% | 2.66B | |
| -60.35% | 2.66B | |
| -7.55% | 2.39B | |
| -9.18% | 1.77B |
- Stock Market
- Equities
- MYGN Stock
